Zevra Therapeutics, Inc. Debt Securities, Available-for-sale, Noncurrent
Zevra Therapeutics, Inc. (ZVRA) had Debt Securities, Available-for-sale, Noncurrent of $38.61 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $38.61M.
- 2026-03-31: Debt Securities, Available-for-sale, Noncurrent $36.15M.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $47.88M.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $30.86M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2026-06-30 | $38.61M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $36.15M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $47.88M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $30.86M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $15.09M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $6.09M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $6.01M 10-K · filed 2026-03-09 |
| 2024-09-30 | $6.11M 10-Q · filed 2024-11-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-12 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-07 |
| 2021-12-31 | $14.93M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |